Harrow's products compete against established generics, and it heavily relies on marketing and sales force expansion to drive ...

Bausch + Lomb is headed by Brent Saunders, a longtime pharmaceutical executive known for leading Allergan into a much ... antitrust issues given its Restasis has a 45% share of the prescription ...

Allergan Aesthetics intends to develop onabotulinumtoxinA treatment for MMP in additional global markets and expand the use of BOTOX ® Cosmetic in the lower face. IRVINE, Calif., Sept.

IRVINE, Calif., Sept. 11, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced that BOTOX ® Cosmetic (onabotulinumtoxinA) is now available for the treatment of ...

On August 13, 2024, the Federal Circuit issued its decision in Allergan USA, Inc. v. MSN Laboratories Private Ltd., No. 24-1061,[1] which limits the scope of obviousness-type double patenting for ...

Allergan's ageing Restasis, meanwhile, is also facing the threat of generic competition, so there's a lot to play for and no shortage of hopefuls aiming to break into the market.

A federal judge has thrown out patents protecting Allergan’s blockbuster dry-eye drug Restasis, and has criticised its related deal with a Native American tribe. In the ruling US Circuit Judge ...